Fresenius Medical Care AG (NYSE:FMS - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $29.85, but opened at $30.46. Fresenius Medical Care shares last traded at $30.32, with a volume of 96,041 shares trading hands.
Analyst Ratings Changes
Several research analysts have recently issued reports on the stock. Morgan Stanley reaffirmed an "underweight" rating on shares of Fresenius Medical Care in a research note on Thursday, May 15th. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Tuesday. They set a "strong-buy" rating on the stock. Finally, Truist Financial raised their price target on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday, May 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Fresenius Medical Care currently has an average rating of "Hold" and a consensus target price of $27.80.
Check Out Our Latest Research Report on FMS
Fresenius Medical Care Stock Up 1.2%
The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm's 50 day moving average is $25.22 and its two-hundred day moving average is $23.84. The firm has a market capitalization of $17.72 billion, a P/E ratio of 24.95, a PEG ratio of 0.76 and a beta of 0.85.
Fresenius Medical Care (NYSE:FMS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.01. The company had revenue of $5.54 billion for the quarter, compared to analyst estimates of $4.71 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. Research analysts predict that Fresenius Medical Care AG will post 1.51 EPS for the current year.
Fresenius Medical Care Increases Dividend
The firm also recently announced an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 23rd will be given a $0.7871 dividend. This represents a dividend yield of 1.9%. The ex-dividend date is Friday, May 23rd. This is a boost from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's payout ratio is presently 49.11%.
Institutional Investors Weigh In On Fresenius Medical Care
A number of institutional investors have recently modified their holdings of FMS. JPMorgan Chase & Co. raised its stake in Fresenius Medical Care by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company's stock valued at $211,000 after purchasing an additional 1,528 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Fresenius Medical Care by 2.2% in the fourth quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company's stock valued at $1,456,000 after purchasing an additional 1,398 shares in the last quarter. Blue Trust Inc. raised its stake in Fresenius Medical Care by 15.6% in the fourth quarter. Blue Trust Inc. now owns 14,876 shares of the company's stock valued at $317,000 after purchasing an additional 2,013 shares in the last quarter. DAVENPORT & Co LLC raised its stake in Fresenius Medical Care by 1.5% in the fourth quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock valued at $1,316,000 after purchasing an additional 862 shares in the last quarter. Finally, Yousif Capital Management LLC acquired a new position in Fresenius Medical Care during the fourth quarter worth about $208,000. Institutional investors own 8.37% of the company's stock.
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
